Spinocerebellar Ataxia Type 6 (Sca6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinocerebellar Ataxia type 6 (SCA6) is a rare, autosomal dominant, late-onset [neurodegenerative disease] characterized by slowly progressive cerebellar ataxia, dysarthria, and nystagmus. It is caused by a CAG trinucleotide repeat expansion in the CACNA1A gene on chromosome 19p13.13, which encodes the alpha-1A subunit of P/Q-type voltage-gated calcium channels (Cav2.1). SCA6 is unique among [polyglutamine diseases] in that the affected protein is a voltage-gated calcium channel subunit, making it simultaneously a channelopathy and a polyglutamine disorder1.
SCA6 is one of over 40 genetically distinct subtypes of Spinocerebellar Ataxia. It has a global prevalence of less than 1 per 100,000 individuals, with the highest frequency in Japan where it accounts for up to 31% of all autosomal dominant cerebellar ataxias2. The disease typically manifests between ages 43 and 52, with a range from 19 to 73 years, and is generally compatible with a normal lifespan, distinguishing it from many other SCAs3.
SCA6 is considered the prototype of a "pure" cerebellar ataxia with minimal extra-cerebellar involvement. The neuropathology reveals selective degeneration of Purkinje cells in the cerebellum, particularly in the cerebellar vermis, with relative preservation of other brain structures4.
SCA6 follows an autosomal dominant inheritance pattern with essentially complete penetrance1:
| Allele Type |
CAG Repeat Count |
Significance |
| Normal |
4-18 repeats |
Non-pathogenic |
| Intermediate/Uncertain |
19-20 repeats |
Uncertain penetrance |
| Pathogenic (full penetrance) |
20-33 repeats |
Disease-causing |
| Most common pathogenic allele |
22 repeats |
Typical expansion |
Unlike most other [polyglutamine disorders] such as Huntington's disease or [SCA1], SCA6 does not show significant intergenerational instability of the repeat. The CAG repeat expansions are relatively stable during transmission, so anticipation (earlier onset in successive generations) is generally not observed5.
The CACNA1A gene encodes two distinct proteins through a bicistronic mechanism discovered in 20136:
- Alpha-1A subunit (Cav2.1): The pore-forming subunit of P/Q-type voltage-gated [calcium] channels, critical for neurotransmitter release at fast synapses throughout the central nervous system
- Alpha-1ACT: A transcription factor produced via an internal ribosome entry site (IRES), which coordinates expression of genes involved in neural development and Purkinje cell differentiation
The polyglutamine tract expanded in SCA6 resides within the alpha-1ACT protein. When expanded, alpha-1ACT loses its transcription factor function and gains toxic properties6.
SCA6 is one of four allelic disorders caused by mutations in CACNA1A:
| Disorder |
Mutation Type |
Key Features |
| SCA6 |
CAG repeat expansion (20-33) |
Late-onset progressive cerebellar ataxia |
| Episodic Ataxia Type 2 (EA2) |
Loss-of-function mutations |
Episodic ataxia; responds to acetazolamide |
| Familial Hemiplegic Migraine Type 1 (FHM1) |
Gain-of-function missense |
Hemiplegic migraine with or without ataxia |
| CACNA1A epileptic encephalopathy |
Haploinsufficiency |
Cognitive impairment, epilepsy, mild cerebellar signs |
SCA6 pathophysiology is multifaceted, involving at least three interrelated mechanisms7:
P/Q-type voltage-gated calcium channels are particularly abundant in cerebellar Purkinje cells and granule cells. The polyglutamine expansion in SCA68:
- Shifts the voltage dependence of channel activation
- Alters the rate of channel inactivation
- Impairs normal G-protein regulation of P/Q-type channels
- Leads to excessive [calcium] ion entry into Purkinje cells, contributing to excitotoxicity
Despite the relatively small polyglutamine expansion (20-33 repeats, the smallest of any polyQ disorder), SCA6 exhibits toxic protein aggregation4:
- Cytoplasmic aggregates of the C-terminal fragment containing the expanded polyQ tract accumulate in Purkinje cells
- The expanded alpha-1ACT transcription factor forms toxic aggregates
- Nuclear inclusions containing mutant protein are found in affected neurons
The expanded alpha-1ACT protein fails to properly regulate expression of genes involved in Purkinje cell development and maintenance, contributing to progressive [neurodegeneration]. Recent research has also identified impaired mitophagy in SCA6 Purkinje cells and reduced BDNF-TrkB signaling9.
Postmortem studies reveal:
- Selective and marked degeneration of cerebellar Purkinje cells
- Atrophy most pronounced in the cerebellar vermis and flocculus
- Combined Purkinje cell and granule cell degeneration in some cases
- Evidence of trans-synaptic degeneration
- Relative preservation of brainstem and cerebral cortex
SCA6 presents as a slowly progressive, predominantly cerebellar syndrome3:
Initial symptoms (in approximately 90% of cases): Gait unsteadiness, stumbling, and imbalance. In approximately 10%, dysarthria is the first symptom.
Core clinical features:
- Progressive gait ataxia
- Upper-limb incoordination and intention tremor
- Cerebellar dysarthria (slurred, scanning speech)
Oculomotor dysfunction is a hallmark of SCA6:
- Horizontal gaze-evoked nystagmus (70-100% of patients)
- Downbeat vertical nystagmus (65-83%, highly characteristic)
- Diplopia and difficulty fixating on moving objects
- Dysphagia and choking (common in later stages)
- Hyperreflexia and extensor plantar responses (40-50%)
- Basal ganglia signs including dystonia and blepharospasm (up to 25%)
- Some patients initially present with episodic ataxia before progression
- Cognition is generally preserved (though mild cerebellar cognitive deficits are reported)
- Peripheral nerve function is mostly intact (79% show no neuropathy)
SCA6 progresses more slowly than [SCA1], [SCA2], or [SCA3]. The annual SARA (Scale for the Assessment and Rating of Ataxia) score increase is approximately 0.81 points per year. Most patients require wheelchair assistance by their sixties10.
SCA6 should be suspected in individuals with adult-onset, slowly progressive cerebellar ataxia with prominent dysarthria and nystagmus (especially downbeat nystagmus), particularly with autosomal dominant family history.
Molecular genetic testing is the gold standard: PCR-based determination of CAG repeats in the CACNA1A gene. Finding 20 or more CAG repeats confirms the diagnosis11.
MRI reveals essentially pure cerebellar atrophy, particularly of the cerebellar vermis, with the brainstem and cerebral hemispheres typically spared.
- Other autosomal dominant cerebellar ataxias ([SCA1], [SCA2], [SCA3]
- Episodic ataxia type 2 (allelic disorder, episodic rather than progressive)
- multiple system atrophy, cerebellar type (MSA-C)
- Sporadic adult-onset ataxia of unknown etiology
- Friedreich's Ataxia (autosomal recessive)
There is currently no disease-modifying therapy or cure for SCA6. Management is symptomatic and supportive12.
- Acetazolamide: Beneficial for some patients, especially those with episodic ataxia-like presentations
- 4-Aminopyridine (fampridine): A potassium channel blocker that can improve nystagmus and oscillopsia symptoms
- Riluzole: Modest improvement in motor scores across hereditary ataxias
- Physical therapy and rehabilitation for balance and mobility
- Occupational therapy for activities of daily living
- Speech therapy for dysarthria and dysphagia
- Assistive devices and fall prevention strategies
- L-Arginine: A Phase 2 trial in Japan (2024) showed improvement of 0.96 SARA points; it inhibits conformational change and aggregation of polyQ proteins13
- miRNA-mediated therapy: AAV9-delivered miR-3191-5p blocks IRES-driven translation of toxic alpha-1ACT, preventing ataxia and Purkinje cell degeneration in mice while preserving normal calcium channel function14
- TrkB-Akt signaling restoration: Exercise and the TrkB agonist 7,8-dihydroxyflavone rescued motor coordination in SCA6 mice9
SCA6 prevalence varies significantly by geography due to founder effects15:
| Region |
SCA6 as % of ADCA |
Notes |
| Western Japan (Chugoku/Kansai) |
Up to 31% |
Strong founder effect |
| Germany |
13-22% |
|
| United States |
12-15% |
|
| South Korea |
7% |
|
| United Kingdom |
~5% |
Point prevalence 1.59/100,000 |
| France/Spain |
1-2% |
|
The high prevalence in Western Japan, particularly around the Seto Inland Sea, is attributed to a founder effect. Global haplotype analysis suggests pathogenic expansions are associated with a common CACNA1A haplotype across populations worldwide16.
- Rolling Nagoya mouse: Natural mutant with missense mutation in Cacna1a, used for drug testing
- SCA6 knock-in mice: Generated with varying CAG repeats (14Q, 30Q, 84Q), modeling human disease progression17
- iPSC-derived neuronal models: Patient-derived neurons used to study bicistronic CACNA1A expression18
- miRNA therapy targeting the CACNA1A second cistron (alpha-1ACT) selectively reduces the toxic protein while preserving essential calcium channel function14
- Antisense oligonucleotides (ASOs): Preclinical work showing phenotype improvement
- FDA-approved drug repurposing: Screening for small molecules that selectively reduce polyQ-containing alpha-1ACT levels
The study of Spinocerebellar Ataxia Type 6 (Sca6) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Zhuchenko et al., Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha1A-voltage-dependent calcium channel (1997)]https://pubmed.ncbi.nlm.nih.gov/8988170/)
- [Mantuano et al., Molecular epidemiology of Spinocerebellar Ataxia type 6 (2004)]https://pubmed.ncbi.nlm.nih.gov/15122720/)
- [Gomez CM, Spinocerebellar Ataxia Type 6 - GeneReviews (1998, updated 2019)]https://www.ncbi.nlm.nih.gov/books/NBK1140/)
- [Frontali M, Spinocerebellar Ataxia type 6: review and neuropathology (2001)]https://pubmed.ncbi.nlm.nih.gov/21827907/)
- [Matsuyama et al., Molecular features of the CAG repeats of Spinocerebellar Ataxia 6 (1997)]https://pubmed.ncbi.nlm.nih.gov/9371901/)
- [Du et al., Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6 (2013, Cell)]https://pubmed.ncbi.nlm.nih.gov/23827678/)
- [Kordasiewicz et al., Molecular mechanism of SCA6: glutamine repeat disorder, channelopathy and transcriptional dysregulation (2015)]https://pmc.ncbi.nlm.nih.gov/articles/PMC4329791/)
- [Toru et al., Spinocerebellar Ataxia type 6 mutation alters P-type calcium channel function (2000, Journal of Neuroscience)]https://pubmed.ncbi.nlm.nih.gov/10964945/)
- [Bhatt et al., Activation of TrkB-Akt signaling rescues deficits in a mouse model of SCA6 (2022, Science Advances)]https://pubmed.ncbi.nlm.nih.gov/36112675/)
- [Jacobi et al., Long-term disease progression in Spinocerebellar Ataxia types 1, 2, 3, and 6: a longitudinal cohort study (2015, Lancet Neurology)]https://pubmed.ncbi.nlm.nih.gov/26377379/)
- [Coutelier et al., Redefining the Pathogenic CAG Repeat Units Threshold in CACNA1A for SCA6 (2025)]https://pubmed.ncbi.nlm.nih.gov/39996131/)
- [Tsuji et al., Current and emerging treatment modalities for spinocerebellar ataxias (2022)]https://pmc.ncbi.nlm.nih.gov/articles/PMC9048095/)
- [Noma et al., L-arginine in patients with Spinocerebellar Ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2024)]https://pubmed.ncbi.nlm.nih.gov/39764542/)
- [Kordasiewicz et al., An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron (2016, Science Translational Medicine)]https://pubmed.ncbi.nlm.nih.gov/27412786/)
- [Craig et al., Pathogenic expansions of the SCA6 locus are associated with a common CACNA1A haplotype across the globe (2008)]https://pubmed.ncbi.nlm.nih.gov/18285829/)
- [Yabe et al., Spinocerebellar Ataxia type 6: founder effect in Western Japan (2004)]https://pubmed.ncbi.nlm.nih.gov/15026160/)
- [Watase et al., Spinocerebellar Ataxia type 6 knockin mice develop progressive neuronal dysfunction (2008, PNAS)]https://www.pnas.org/doi/10.1073/pnas.0804350105)
- [Bavassano et al., Bicistronic CACNA1A gene expression in neurons derived from SCA6 patient-induced pluripotent stem cells (2017)]https://pubmed.ncbi.nlm.nih.gov/28946818/)